C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 76 filers reported holding C4 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,067 | -47.7% | 2,186,459 | -22.7% | 0.00% | 0.0% |
| Q2 2023 | $7,780 | -13.8% | 2,828,605 | -1.6% | 0.00% | 0.0% |
| Q1 2023 | $9,029 | -47.7% | 2,875,374 | -1.7% | 0.00% | -66.7% |
| Q4 2022 | $17,259 | -99.9% | 2,925,253 | -1.3% | 0.00% | -25.0% |
| Q3 2022 | $25,996,000 | -21.3% | 2,964,056 | -32.4% | 0.00% | 0.0% |
| Q2 2022 | $33,049,000 | -68.9% | 4,383,163 | +0.1% | 0.00% | -63.6% |
| Q1 2022 | $106,195,000 | -19.3% | 4,377,372 | +7.2% | 0.01% | -8.3% |
| Q4 2021 | $131,530,000 | -25.6% | 4,084,798 | +3.2% | 0.01% | -29.4% |
| Q3 2021 | $176,832,000 | +31.8% | 3,957,743 | +11.6% | 0.02% | +41.7% |
| Q2 2021 | $134,137,000 | +72.9% | 3,544,837 | +69.0% | 0.01% | +50.0% |
| Q1 2021 | $77,598,000 | +57.1% | 2,097,809 | +37.1% | 0.01% | +60.0% |
| Q4 2020 | $49,381,000 | – | 1,530,042 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |